large B-cell lymphoma
FDA Approves Adcetris With Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma
The FDA has approved brentuximab vedotin (Adcetris, Seagen, a subsidiary of Pfizer) in combination with ...
FEBRUARY 19, 2025
Columvi Granted Accelerated Approval For Selected Relapsed or Refractory Large B-cell Lymphomas
The FDA granted accelerated approval for glofitamab-gxbm (Columvi, Genentech) for the treatment of adult patients ...
JUNE 18, 2023
New CAR T-Cell Therapy Approved for LBCL
The FDA approved lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb), a CD19-directed chimeric antigen ...
JUNE 24, 2022
Off-the-Shelf Allogeneic CAR T-Cell Therapy Shows Promise
A novel allogeneic chimeric antigen receptor T-cell therapy, ALLO-501A, showed encouraging safety and efficacy in a ...
FEBRUARY 17, 2022
Zynlonta Approved for Relapsed or Refractory Large B-Cell Lymphomas
The FDA granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics) for the treatment ...
MAY 5, 2021
New CAR T-Cell Therapy Breyanzi Approved for R/R B-Cell Lymphoma
The FDA approved the CD19-directed chimeric antigen receptor T-cell immunotherapy lisocabtagene maraleucel ...
FEBRUARY 12, 2021
